R J Flores1, K R Flaherty2, Z Jin3, S Bokhari2. 1. Internal Medicine, Columbia University Medical Center, New York, NY, USA. raul.jesus.flores@gmail.com. 2. Internal Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, USA. 3. Department of Biostatistics, Columbia University, New York, NY, USA.
Abstract
BACKGROUND: There is no identified level of FDG uptake in cardiac sarcoidosis (CS) associated with increased risk of arrhythmias, conduction disease, heart failure, or death. We aim to utilize standardized uptake value (SUV) quantitation and localization to identify patients at increased risk of cardiac events. METHODS AND RESULTS: F18-FDG PET/CT with MPI was used in CS diagnosis (N = 67). Mean and max SUV were measured and grouped as basal, mid, and apical disease. Post-scan ventricular tachycardia, AICD placement, complete heart block, pacemaker placement, atrial fibrillation, heart failure, and cardiac-related hospital admissions were recorded (mean follow up 2.98 ± 2 years). Poisson regression analysis revealed that max SUV, mean SUV, as well as mean basal SUV, and LVEF were significantly associated with total cardiac events. Max SUV odds ratio (OR) = 1.068 (95% CI 1.024-1.114, P = 0.002), mean SUV OR = 1.059 (95% CI 1.008-1.113, P = 0.023), mean SUV OR = 1.061 (95% CI 1.012-1.112, P = 0.014), scan LVEF OR = 0.731 (95% CI 0.664-0.805, P < 0.001). CONCLUSIONS: SUV at time of CS diagnosis has significant associations with future cardiac events. Patients with higher SUV, particularly in basal segments, are at increased risk of events. Further studies are needed to identify treatment methods utilizing risk stratification of CS.
BACKGROUND: There is no identified level of FDG uptake in cardiac sarcoidosis (CS) associated with increased risk of arrhythmias, conduction disease, heart failure, or death. We aim to utilize standardized uptake value (SUV) quantitation and localization to identify patients at increased risk of cardiac events. METHODS AND RESULTS: F18-FDG PET/CT with MPI was used in CS diagnosis (N = 67). Mean and max SUV were measured and grouped as basal, mid, and apical disease. Post-scan ventricular tachycardia, AICD placement, complete heart block, pacemaker placement, atrial fibrillation, heart failure, and cardiac-related hospital admissions were recorded (mean follow up 2.98 ± 2 years). Poisson regression analysis revealed that max SUV, mean SUV, as well as mean basal SUV, and LVEF were significantly associated with total cardiac events. Max SUV odds ratio (OR) = 1.068 (95% CI 1.024-1.114, P = 0.002), mean SUV OR = 1.059 (95% CI 1.008-1.113, P = 0.023), mean SUV OR = 1.061 (95% CI 1.012-1.112, P = 0.014), scan LVEF OR = 0.731 (95% CI 0.664-0.805, P < 0.001). CONCLUSIONS: SUV at time of CS diagnosis has significant associations with future cardiac events. Patients with higher SUV, particularly in basal segments, are at increased risk of events. Further studies are needed to identify treatment methods utilizing risk stratification of CS.
Authors: Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein Journal: J Nucl Cardiol Date: 2017-10 Impact factor: 5.952
Authors: Pablo B Nery; Rob S Beanlands; Girish M Nair; Martin Green; Jim Yang; Brian A McArdle; Darryl Davis; Hiroshi Ohira; Michael H Gollob; Eugene Leung; Jeff S Healey; David H Birnie Journal: J Cardiovasc Electrophysiol Date: 2014-05-02
Authors: Brett W Sperry; Balaji K Tamarappoo; Jorge D Oldan; Omair Javed; Daniel A Culver; Richard Brunken; Manuel D Cerqueira; Rory Hachamovitch Journal: JACC Cardiovasc Imaging Date: 2017-08-16
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Patrizio Lancellotti; Fabien Hyafil; Ron Blankstein; Ronald G Schwartz; Wael A Jaber; Raymond Russell; Alessia Gimelli; François Rouzet; Marcus Hacker; Olivier Gheysens; Sven Plein; Edward J Miller; Sharmila Dorbala; Erwan Donal Journal: J Nucl Cardiol Date: 2018-02 Impact factor: 5.952
Authors: Riina Kandolin; Jukka Lehtonen; Juhani Airaksinen; Tapani Vihinen; Heikki Miettinen; Kari Ylitalo; Kari Kaikkonen; Suvi Tuohinen; Petri Haataja; Tuomas Kerola; Jorma Kokkonen; Markus Pelkonen; Päivi Pietilä-Effati; Seppo Utrianen; Markku Kupari Journal: Circulation Date: 2014-12-19 Impact factor: 29.690
Authors: Daniele Muser; Pasquale Santangeli; Simon A Castro; Jackson J Liang; Andres Enriquez; Thomas J Werner; Gaetano Nucifora; Silvia Magnani; Tatsuya Hayashi; Erica S Zado; Fermin C Garcia; David J Callans; Sanjay Dixit; Benoit Desjardins; Francis E Marchlinski; Abass Alavi Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-02 Impact factor: 9.236